首页|Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy

Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy

扫码查看
原文链接
  • 万方数据
  • 维普
The advent of cancer immunotherapy has imparted a transformative impact on cancer treatment paradigms by harnessing the power of the immune system.However,the challenge of practical and precise targeting of malignant cells persists.To address this,engineered nanoparticles(NPs)have emerged as a promising solution for enhancing targeted drug delivery in immunotherapeutic interventions,owing to their small size,low immunogenicity,and ease of surface modification.This comprehensive review delves into contemporary research at the nexus of NP engineering and immunotherapy,encompassing an extensive spectrum of NP morphologies and strategies tailored toward optimizing tumor targeting and augmenting therapeutic effectiveness.Moreover,it underscores the mechanisms that NPs leverage to bypass the numerous obstacles encountered in immunotherapeutic regimens and probes into the combined potential of NPs when co-administered with both established and novel immunotherapeutic modalities.Finally,the review evaluates the existing limitations of NPs as drug delivery platforms in immunotherapy,which could shape the path for future advancements in this promising field.

Engineered nanoparticlesCancer immunotherapyDrug deliveryBlood-brain barrierTumor-barrierNanomedicineNanomaterialCancer

Xueqiang Peng、Jianjun Fang、Chuyuan Lou、Liang Yang、Shaobo Shan、Zixian Wang、Yutong Chen、Hangyu Li、Xuexin Li

展开 >

Department of General Surgery,The Fourth Affiliated Hospital,China Medical University,Shenyang 110032,China

Department of Ophthalmology,Xi'an People's Hospital(Xi'an Fourth Hospital),Xi'an 710004,China

Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 10050,China

Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center of Cancer Medicine,Guangzhou 510060,China

Department of Pathology,Medical College,Jinan University,Guangzhou 510632,China

Department of Physiology and Pharmacology,Karolinska Institutet,Stockholm SE-17177,Sweden

展开 >

Karolinska Institute Network Medicine Global Alliance Collaborative GrantKarolinska Institute Network Medicine Global Alliance Collaborative GrantChina Postdoctoral Science FoundationNatural Science Foundation of Liaoning Province,China

C24401073Sweden2021M7036022022-BS-137

2024

10.1016/j.apsb.2024.05.010

药学学报(英文版)

药学学报(英文版)

CSTPCD
ISSN：
年,卷(期)：2024.14(8)